Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP
Clinical relevance of IgG isotype
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published November 21, 2019.
Author Disclosures
- Andrea Cortese, MD, PhD,
- Raffaella Lombardi, MA,
- Chiara Briani, MD,
- Ilaria Callegari, MD,
- Luana Benedetti, MD, PhD,
- Fiore Manganelli, MD,
- Marco Luigetti, MD, PhD,
- Sergio Ferrari, MD,
- Angelo M. Clerici, MD,
- Girolama Alessandra Marfia, MD,
- Andrea Rigamonti, MD,
- Marinella Carpo, MD, PhD,
- Raffaella Fazio, MD,
- Massimo Corbo, MD,
- Anna Mazzeo, MD,
- Fabio Giannini, MD,
- Giuseppe Cosentino, MD, PhD,
- Elisabetta Zardini, MA,
- Riccardo Currò, MD,
- Matteo Gastaldi, MD, PhD,
- Elisa Vegezzi, MD,
- Enrico Alfonsi, MD,
- Angela Berardinelli, MD,
- Ludivine Kouton, MD,
- Constance Manso, MSc,
- Claudia Giannotta, MA,
- Pietro Doneddu, MD,
- Patrizia Dacci, MD, PhD,
- Laura Piccolo, MD,
- Marta Ruiz, MD,
- Alessandro Salvalaggio, MD,
- Chiara De Michelis, MD,
- Emanuele Spina, MD,
- Antonietta Topa, MD,
- Giulia Bisogni, MD,
- Angela Romano, MD,
- Sara Mariotto, MD,
- Giorgia Mataluni, MD, PhD,
- Federica Cerri, MD, PhD,
- Claudia Stancanelli, MD,
- Mario Sabatelli, MD,
- Angelo Schenone, MD,
- Enrico Marchioni, MD,
- Giuseppe Lauria, MD,
- Eduardo Nobile-Orazio, MD,
- Jérôme Devaux, PhD* and
- Diego Franciotta, MD*
- Andrea Cortese, MD, PhD,
Pfizer Polyneuropathy Advisory Board
NONE
NONE
Editorial Advisory Board Member of Journal of the Peripheral Nervous System
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Inherited neuropathy consortium, which is a part of the NIH Rare Diseases Clinical Research Network (RDCRN) (U54NS065712) and Wellcome Trust (204841/Z/16/Z).
NONE
NONE
NONE
NONE
NONE
NONE
- Raffaella Lombardi, MA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chiara Briani, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ilaria Callegari, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luana Benedetti, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fiore Manganelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marco Luigetti, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Ferrari, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angelo M. Clerici, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Girolama Alessandra Marfia, MD,
Advisory Board Member of: (1) Biogen (2) Genzyme (3) Merck-Serono (4) Novartis (5) Teva
NONE
Travel funding from the following commercial entities: (1) Almirall (2) Bayer Schering (3) Biogen Idec (4) Genzyme (5) Merck Serono (6) Novartis (7) Teva
NONE
NONE
NONE
NONE
Consultation fees from (1) Almirall (2) Bayer Schering (3) Biogen Idec (4) Genzyme (5) Merck Serono (6) Novartis (7) Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrea Rigamonti, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marinella Carpo, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Raffaella Fazio, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Massimo Corbo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna Mazzeo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Fabio Giannini, MD,
NONE
NONE
Commercial entities (Pharmaceutical company: (1)Kedrion, (2)Grifols, (3)CSL, (4)Genzyme, (5)Angelini for payment of travel-related expenses and (6) Italfarmaco for educational activity Non-profit entity:(7)NIBIT Onlus Foundation for educational activity
NONE
NONE
NONE
NONE
NONE
NONE
(1)Non-profit entity: Istituto Farmacologico
NONE
(1) Pharmaceutical company AB Science,investigator in clinical trial(non-principal) (2)Pharmaceutical company CLS: research support for INSTANT project
(1)Ricerca Finalizzata (Ministero Salute)2016: Project Code RF-2016-02363688 - Principal Investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giuseppe Cosentino, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elisabetta Zardini, MA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Riccardo Currò, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matteo Gastaldi, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elisa Vegezzi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Enrico Alfonsi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Berardinelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ludivine Kouton, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Constance Manso, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Giannotta, MA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pietro Doneddu, MD,
NONE
NONE
Travel grants to attend scientific meetings from Kedrion and CSL Behring
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrizia Dacci, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laura Piccolo, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marta Ruiz, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessandro Salvalaggio, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chiara De Michelis, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emanuele Spina, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Antonietta Topa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giulia Bisogni, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Romano, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sara Mariotto, MD,
NONE
NONE
(1) Support for attending scientific meetings by Merck and Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giorgia Mataluni, MD, PhD,
NONE
NONE
Travel funding from Kedrion, CSL Bering, Almirall, Biogen, Novartis and Sanofi- Genzyme; honoraria for speaking from Biogen. She is subinvestigator in clinical trials being conducted for Biogen, Merck Serono, Novartis, Roche and Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Federica Cerri, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Claudia Stancanelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mario Sabatelli, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angelo Schenone, MD,
NONE
NONE
NONE
Frontiers Neurology, subeditor, 2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Enrico Marchioni, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Giuseppe Lauria, MD,
GL served on scientific advisory board of Vertex, Biogen, Chromocell, CSL Behring
NONE
NONE
Editor-in-Chief, Journal of the Peripheral Nervous System, 2019-
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eduardo Nobile-Orazio, MD,
1) Kedrion, Italy, 2) Baxter, Italy, 3) Novartis, Switzerland, 4) CSL-Behring, Italy and USA, 5) LFB, France, 6) Astellas, the Netherlands
NONE
1) Kedrion, Italy, speaker honorarium 2) CSL Behring, Italy and USA, speaker honorarium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) AIFA, Ricerca Indipendente 2016:
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme Devaux, PhD* and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
CSL Behring?s grant in immunology.
NONE
NONE
1) Agence Nationale pour la Recherche (NECCIN)2) the Association Française contre les Myopathies (21532)
NONE
NONE
NONE
NONE
NONE
NONE
- Diego Franciotta, MD*
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Brain and Behavioral Sciences (A.C., I.C., G.C., R.C., E.V.), University of Pavia, Pavia, Italy; Department of Neuromuscular Disease (A.C.), UCL Queen Square Institute of Neurology, London, United Kingdom; Neuroalgology Unit (R.L., P.D., L.P., G.L.), IRCCS Fondazione Istituto Neurologico “Carlo Besta,” Milan, Italy; Department of Neurosciences (C.B., M.R., A.S.), University of Padova, Padova, Italy; IRCCS Mondino Foundation (I.C., G.C., E.Z., R.C., M.G., E.V., E.A., A.B., D.F.), Pavia, Italy; Department of Neuroscience (L.B., C.D.M., A.S.), Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Genova, Italy; IRCCS Ospedale Policlinico San Martino (L.B., C.D.M., A.S.), Genova, Italy; Department of Neurosciences (F.M., E.S., A.T.), Odontostomatological and Reproductive Sciences, University of Naples “Federico II,” Naples, Italy; Fondazione Policlinico Universitario Agostino Gemelli-IRCCS. UOC Neurologia (M.L., A.R., M.S.), Rome, Italy; Università Cattolica del Sacro Cuore (M.L., A.R., M.S.), Rome, Italy; Section of Neurology (S.F., S.M.), Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy; Department of Neurology and Stroke Unit (A.M.C.), Ospedale di Circolo/Fondazione Macchi, Varese, Italy; Department of Systems Medicine (G.A.M., G.M.), University of Rome Tor Vergata, Rome, Italy; Neurological Department (A.R.), ASST Lecco; Ospedale Treviglio ASST Bergamo Ovest (M.C.), Italy; Department of Neurology (R.F., F.C.), San Raffaele Scientific Institute, Milan, Italy; Department of Neurorehabilitation Sciences (M.C.), Casa Cura Policlinico (CCP), Milan, Italy; Department of Clinical and Experimental Medicine (A.M.), University of Messina, Messina, Italy; Department of Medicine, Surgery and Neurosciences (F.G.), University of Siena, Italy; Referral Center for Neuromuscular Diseases and ALS (L.K., E.M.), AP-HM, Timone University Hospital, Marseille, France; Université de Bordeaux (C.M.), Interdisciplinary Institute for Neuroscience, Bordeaux, France; Humanitas Clinical and Research Center (C.G., P.D., E.N.-O.), Milan University, Milan, Italy; IRCCS Centro Neurolesi “Bonino Pulejo” (C.S.), Messina, Italy; Department of Biomedical and Clinical Sciences “Luigi Sacco” (G.B., G.L.), University of Milan, Milan, Italy; and Institute for Neurosciences of Montpellier (J.D.), INSERM U1051, Montpellier University, Hopital Saint Eloi, Montpellier, France.
- Correspondence
Dr. Cortese andrea.cortese{at}ucl.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathyLuise Appeltshauser, Anna-Michelle Brunder, Annika Heinius et al.Neurology: Neuroimmunology & Neuroinflammation, July 24, 2020 -
Article
Anti-neurofascin antibody in patients with combined central and peripheral demyelinationNobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa et al.Neurology, July 24, 2013 -
Article
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIgLuis Querol, Gisela Nogales-Gadea, Ricardo Rojas-Garcia et al.Neurology, February 12, 2014 -
Clinical/Scientific Notes
Neurofascin-155 as a putative antigen in combined central and peripheral demyelinationAndrea Cortese, Jérôme J. Devaux, Elisabetta Zardini et al.Neurology: Neuroimmunology & Neuroinflammation, June 07, 2016